Noesis Capital Mangement Corp reduced its position in Gilead Sciences (NASDAQ:GILD) by 1.7% in the fourth quarter, Holdings Channel reports. The fund owned 100,319 shares of the biopharmaceutical company’s stock after selling 1,705 shares during the period. Gilead Sciences makes up about 2.5% of Noesis Capital Mangement Corp’s investment portfolio, making the stock its 16th largest position. Noesis Capital Mangement Corp’s holdings in Gilead Sciences were worth $7,187,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Rowland & Co. Investment Counsel ADV purchased a new stake in Gilead Sciences during the 2nd quarter valued at $153,000. Stonebridge Capital Advisors LLC raised its stake in Gilead Sciences by 260.6% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 73,943 shares of the biopharmaceutical company’s stock valued at $5,234,000 after buying an additional 53,440 shares during the last quarter. Scotia Capital Inc. raised its stake in Gilead Sciences by 9.8% during the 2nd quarter. Scotia Capital Inc. now owns 146,411 shares of the biopharmaceutical company’s stock valued at $10,362,000 after buying an additional 13,078 shares during the last quarter. Linscomb & Williams Inc. raised its stake in Gilead Sciences by 10.1% during the 2nd quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock valued at $411,000 after buying an additional 531 shares during the last quarter. Finally, Chiron Investment Management LLC raised its stake in Gilead Sciences by 42.9% during the 2nd quarter. Chiron Investment Management LLC now owns 266,500 shares of the biopharmaceutical company’s stock valued at $18,863,000 after buying an additional 80,000 shares during the last quarter. Institutional investors own 78.35% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Tuesday. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. Barclays reiterated an “overweight” rating and set a $95.00 target price (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Finally, TheStreet lowered shares of Gilead Sciences from a “b-” rating to a “c” rating in a research note on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $88.65.
Shares of Gilead Sciences stock opened at $73.70 on Friday. The firm has a market capitalization of $98,675.37, a P/E ratio of 8.61, a PEG ratio of -1.71 and a beta of 1.19. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.70 EPS. sell-side analysts forecast that Gilead Sciences will post 6.32 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were issued a $0.57 dividend. The ex-dividend date was Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 3.09%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is currently 26.64%.
In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $73.14, for a total value of $3,657,000.00. Following the completion of the transaction, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $224,376,112.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the transaction, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. Insiders sold a total of 308,600 shares of company stock valued at $24,328,226 in the last ninety days. 1.30% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/21/gilead-sciences-gild-position-trimmed-by-noesis-capital-mangement-corp.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.